Wells Fargo’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.64M | Sell |
118,525
-90,663
| -43% | -$2.17M | ﹤0.01% | 3059 |
|
|
2025
Q4 | $5.59M | Buy |
209,188
+58,385
| +39% | +$1.4M | ﹤0.01% | 2570 |
|
|
2025
Q3 | $3.22M | Buy |
150,803
+12,109
| +9% | +$286K | ﹤0.01% | 2949 |
|
|
2025
Q2 | $2.99M | Sell |
138,694
-61,051
| -31% | -$1.13M | ﹤0.01% | 2891 |
|
|
2025
Q1 | $3.32M | Sell |
199,745
-2,604
| -1% | -$47.3K | ﹤0.01% | 2738 |
|
|
2024
Q4 | $3.71M | Buy |
202,349
+14,447
| +8% | +$233K | ﹤0.01% | 2683 |
|
|
2024
Q3 | $2.89M | Buy |
187,902
+2,185
| +1% | +$36.5K | ﹤0.01% | 2779 |
|
|
2024
Q2 | $3.02M | Buy |
185,717
+83,797
| +82% | +$1.35M | ﹤0.01% | 2640 |
|
|
2024
Q1 | $1.88M | Buy |
101,920
+13,721
| +16% | +$340K | ﹤0.01% | 3016 |
|
|
2023
Q4 | $2.76M | Sell |
88,199
-55,921
| -39% | -$1.34M | ﹤0.01% | 2648 |
|
|
2023
Q3 | $3M | Sell |
144,120
-42,837
| -23% | -$1.16M | ﹤0.01% | 2476 |
|
|
2023
Q2 | $4.48M | Buy |
186,957
+7,730
| +4% | +$172K | ﹤0.01% | 2233 |
|
|
2023
Q1 | $3.37M | Buy |
179,227
+78,190
| +77% | +$1.49M | ﹤0.01% | 2425 |
|
|
2022
Q4 | $1.61M | Sell |
101,037
-2,164
| -2% | -$33.8K | ﹤0.01% | 2935 |
|
|
2022
Q3 | $1.69M | Sell |
103,201
-585
| -0.6% | -$9.47K | ﹤0.01% | 2865 |
|
|
2022
Q2 | $1.46M | Sell |
103,786
-61,757
| -37% | -$1.15M | ﹤0.01% | 3041 |
|
|
2022
Q1 | $4.01M | Sell |
165,543
-38,915
| -19% | -$942K | ﹤0.01% | 2644 |
|
|
2021
Q4 | $4.77M | Buy |
204,458
+8,271
| +4% | +$166K | ﹤0.01% | 2617 |
|
|
2021
Q3 | $3.26M | Buy |
196,187
+37,796
| +24% | +$729K | ﹤0.01% | 3243 |
|
|
2021
Q2 | $3.86M | Buy |
158,391
+3,588
| +2% | +$81K | ﹤0.01% | 3092 |
|
|
2021
Q1 | $3.99M | Sell |
154,803
-22,244
| -13% | -$979K | ﹤0.01% | 3052 |
|
|
2020
Q4 | $9.47M | Sell |
177,047
-24,481
| -12% | -$1.22M | ﹤0.01% | 2127 |
|
|
2020
Q3 | $8.31M | Sell |
201,528
-16,273
| -7% | -$703K | ﹤0.01% | 2032 |
|
|
2020
Q2 | $10.6M | Sell |
217,801
-12,260
| -5% | -$589K | ﹤0.01% | 1812 |
|
|
2020
Q1 | $9.72M | Buy |
230,061
+19,666
| +9% | +$810K | ﹤0.01% | 1686 |
|
|
2019
Q4 | $9M | Buy |
210,395
+3,646
| +2% | +$159K | ﹤0.01% | 2042 |
|
|
2019
Q3 | $7.44M | Buy |
206,749
+7,584
| +4% | +$230K | ﹤0.01% | 2185 |
|
|
2019
Q2 | $5.32M | Buy |
199,165
+30
| +0% | +$766 | ﹤0.01% | 2528 |
|
|
2019
Q1 | $5.35M | Buy |
199,135
+3,866
| +2% | +$90.3K | ﹤0.01% | 2488 |
|
|
2018
Q4 | $3.16M | Buy |
195,269
+11,265
| +6% | +$219K | ﹤0.01% | 2886 |
|
|
2018
Q3 | $3.82M | Sell |
184,004
-95,313
| -34% | -$1.5M | ﹤0.01% | 2873 |
|
|
2018
Q2 | $4.26M | Buy |
279,317
+94,853
| +51% | +$1.69M | ﹤0.01% | 2835 |
|
|
2018
Q1 | $4.14M | Buy |
184,464
+36,951
| +25% | +$1.02M | ﹤0.01% | 2790 |
|
|
2017
Q4 | $4.44M | Sell |
147,513
-25,297
| -15% | -$809K | ﹤0.01% | 2679 |
|
|
2017
Q3 | $6.51M | Sell |
172,810
-2,558
| -1% | -$83.2K | ﹤0.01% | 2314 |
|
|
2017
Q2 | $4.89M | Buy |
175,368
+39,480
| +29% | +$1.18M | ﹤0.01% | 2464 |
|
|
2017
Q1 | $4.67M | Buy |
135,888
+9,608
| +8% | +$339K | ﹤0.01% | 2481 |
|
|
2016
Q4 | $3.64M | Buy |
126,280
+66,772
| +112% | +$1.77M | ﹤0.01% | 2662 |
|
|
2016
Q3 | $1.89M | Sell |
59,508
-76
| -0.1% | -$2.58K | ﹤0.01% | 3019 |
|
|
2016
Q2 | $1.93M | Sell |
59,584
-18,893
| -24% | -$632K | ﹤0.01% | 2999 |
|
|
2016
Q1 | $2.19M | Buy |
78,477
+4,055
| +5% | +$88.4K | ﹤0.01% | 2862 |
|
|
2015
Q4 | $2.65M | Sell |
74,422
-1,318
| -2% | -$46.4K | ﹤0.01% | 2776 |
|
|
2015
Q3 | $2.5M | Buy |
75,740
+25,306
| +50% | +$1.05M | ﹤0.01% | 2833 |
|
|
2015
Q2 | $2.11M | Buy |
50,434
+17,446
| +53% | +$675K | ﹤0.01% | 3059 |
|
|
2015
Q1 | $1.07M | Sell |
32,988
-25,094
| -43% | -$863K | ﹤0.01% | 3491 |
|
|
2014
Q4 | $1.84M | Sell |
58,082
-504
| -0.9% | -$14.3K | ﹤0.01% | 3068 |
|
|
2014
Q3 | $1.45M | Sell |
58,586
-15,682
| -21% | -$367K | ﹤0.01% | 3211 |
|
|
2014
Q2 | $1.68M | Buy |
74,268
+6,502
| +10% | +$136K | ﹤0.01% | 3113 |
|
|
2014
Q1 | $1.65M | Buy |
67,766
+3,287
| +5% | +$83.2K | ﹤0.01% | 3122 |
|
|
2013
Q4 | $1.61M | Buy |
64,479
+41,703
| +183% | +$984K | ﹤0.01% | 3080 |
|
|
2013
Q3 | $626K | Buy |
22,776
+9,236
| +68% | +$193K | ﹤0.01% | 3634 |
|
|
2013
Q2 | $246K | Buy |
+13,540
| New | +$187K | ﹤0.01% | 4041 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Wells Fargo's ACAD Position: Q1 2026 in Review
Wells Fargo reduced its Acadia Pharmaceuticals (ACAD) stake by 43% in Q1 2026, selling an estimated $2.17M and leaving 118,525 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3059.
Wells Fargo first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.6M in Q2 2020. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Wells Fargo held 118,525 shares of Acadia Pharmaceuticals worth $2.64M as of Q1 2026.
- Wells Fargo sold 90,663 Acadia Pharmaceuticals shares in Q1 2026, an estimated $2.17M.
- Acadia Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3059 holding.
- Wells Fargo first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Wells Fargo's Acadia Pharmaceuticals position peaked at $10.6M in Q2 2020.
- 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.